Corvus制药 CRVS 深 沪
已收盘 07-02 16:00:00 美东时间
15.23
+0.470
+3.18%
华盛通- 最 高15.50
- 今 开14.78
- 成交量 131.79万股
- 最 低 14.58
- 昨 收 14.76
- 总市值 12.81亿
- 52周最高 26.95
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 3.96
- 委 比 29.02%
- 总股本 8409.04万
- 历史最高 26.95
- 量 比 0.67
- 振 幅 6.23%
- 历史最低 0.607
- 每 手 1
- 风险率 5.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多These latest Oppenheimer picks earn the highest Quant ratings
Oppenheimer has refreshed its OPCO Trifecta stock list, identifying companies that combine favorable fundamental ratings, positive technical trends and supportive macroeconomic tailwinds, as the firm ...
07-01 19:16
Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the
06-09 19:34
Corvus Pharmaceuticals invests $5 million in Angel Pharma financing round
Corvus Pharmaceuticals invests $5 million in Angel Pharma financing round Corvus Pharmaceuticals invested $5 million in a new $13.5 million financing for China partner Angel Pharmaceuticals. Proceeds support Angel Pharma’s Phase 1b/2 soquelitinib trial in atopic dermatitis and a planned Phase 2 asth
06-09 19:30
Corvus drops after early-stage trial data for eczema therapy
Corvus Pharmaceuticals (CRVS) lost ~13% on Thursday after the biotech posted final data from a Phase 1 trial for its lead candidate, soquelitinib, in patients with atopic dermatitis, an inflammatory s...
05-15 01:00
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Corvus Pharmaceuticals announced positive results from a Phase 1 trial of soquelitinib for moderate-to-severe atopic dermatitis. The trial showed significant clinical efficacy, including sustained remission without rebound, and a favorable safety profile. Soquelitinib inhibits ITK, reducing Th2 and Th17 cell activity while increasing Treg cells, potentially offering a novel treatment approach for autoimmune and inflammatory diseases.
05-14 11:00
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40
Goldman Sachs analyst Paul Choi initiates coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy rating and announces Price Target of $40.
04-17 19:41
电话会总结 ｜ Corvus(CRVS)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Corvus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **研发费用：** 2025年第四季度研发费用为990万美元，全年研发费用为3,370万美元，主要用于soquelitinib的临床试验和制造成本以及人员费用增长。 **净亏损：** 2025年第四季度净亏损1,230万美元，全年净亏损数据未具体披露。亏损中包含Angel Pharmaceuticals股权投资的非现金损失70万美元。 **股权激励费用：** 2025年第四季度股权激励费用为160万美元。 **现金状况：** 截至2025年12月31日，现金、现金等价物和有价
03-16 14:29
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q4 earnings call. Read on fo...
03-14 08:11
BUZZ-U.S. STOCKS ON THE MOVE-PayPay Corp, Ulta Beauty, InMode
BUZZ-U.S. STOCKS ON THE MOVE-PayPay Corp, Ulta Beauty, InMode Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 13 (Reuters) - Wall Street's main stock indexes were set to op
03-13 21:31
